Q1 Earnings Snapshot 2026 – Winners, Surprises & Misses Revealed!

ABB India Q1 FY27 Results Highlights

Maruti Suzuki

CMP: ₹14,234 | M.Cap: ₹4,47,521 Cr | P/E: 31.2x

CDSL – Q1 FY27 Results Snapshot

CMP: ₹1,333 | Market Cap: ₹27,860 Cr | P/E: 59.1

Verdict

CDSL delivered a healthy quarter with strong double-digit growth in revenue and net profit. Profitability improved sequentially, driven by higher operating leverage, with EBITDA and PAT registering robust QoQ gains. The company continues to benefit from increasing investor participation, higher demat account additions, and strong capital market activity. Overall, the results remain positive and reinforce CDSL’s strong business fundamentals and long-term growth outlook.

Sun Pharmaceutical Industries – Q1 FY27 Results

CMP: ₹1,990 | M.Cap: ₹4,77,588 Cr | P/E: 37.8

Aditya Birla Capital Ltd – Q1 FY27 Results

CMP: ₹423 | M.Cap: ₹1,10,623 Cr | P/E: 26.6

Verdict

Aditya Birla Capital reported a strong Q1 FY27 performance, driven by healthy growth in operating profit and a sharp increase in net profit. While revenue declined sequentially, robust margin expansion and improved profitability indicate strengthening business momentum across its financial services portfolio.

Kirloskar Brothers – Q1 FY27 Results

CMP: ₹1,870 | Market Cap: ₹14,850 Cr | P/E: 36.7

Verdict

Kirloskar Brothers reported healthy revenue growth of 13% YoY during Q1 FY27, reflecting steady demand across its business segments. However, operating performance remained subdued, with EBITDA increasing only 4% YoY as margins came under pressure. Net profit and EPS were largely flat compared to the year-ago period and declined sharply on a sequential basis due to lower profitability. Overall, despite solid revenue growth, the quarter was soft as earnings failed to keep pace with sales.

Voltamp Transformers – Q1 FY27 Results

CMP: ₹9,923 | M.Cap: ₹10,039 Cr | P/E: 31.7

Verdict

Intellect Design Arena – Q1 FY27 Results

CMP: ₹720 | M.Cap: ₹10,098 Cr | P/E: 27.3

Verdict

Intellect Design Arena delivered healthy revenue growth with sales rising 20% YoY, reflecting continued business momentum. However, EBITDA and net profit declined sequentially due to margin pressure, resulting in weaker profitability on a QoQ basis. Overall, the company posted a solid year-on-year performance, though the quarter remained soft sequentially because of lower margins and earnings.

ITC Q1 FY27 Results –

Glenmark Pharma – Q1 FY27 Results

CMP: ₹2,234 | M.Cap: ₹63,041 Cr | P/E: 20.2

Note: Jun 2025 included an exceptional item of ₹(323) Cr. YoY growth has been calculated excluding exceptional items.

Verdict

Glenmark Pharma reported a strong quarter with healthy revenue growth, robust EBITDA expansion, and a sharp improvement in profitability. Sequential performance remained positive across all key metrics, reflecting sustained operational momentum. The significant jump in earnings was supported by a strong operating performance, while the adjusted YoY comparison provides a clearer picture by excluding the exceptional loss recorded in the base quarter.

GAIL (India)

CMP: ₹181 | M.Cap: ₹1,19,299 Cr | P/E: 12.1

Verdict

GAIL (India) reported a strong quarter with broad-based earnings growth. Revenue increased steadily, while EBITDA and net profit surged sharply on both YoY and QoQ basis, reflecting significant margin expansion, improved operational efficiency, and healthy business momentum.

IOCL (Standalone) – Q1 FY27 Results

Price: ₹140 | M.Cap: ₹1,97,937 Cr | P/E: 5.9

Verdict

IOCL reported a weak performance in Q1 FY27. While revenue grew strongly on both a sequential and year-on-year basis, operating profitability deteriorated sharply due to significant margin pressure. EBITDA plunged 84% QoQ and 69% YoY, leading to a net loss of ₹1,141 crore despite higher sales. The sharp decline in earnings highlights the impact of weaker refining and marketing margins during the quarter.

Bajaj Holdings – Q1 FY27 Results (Standalone)

CMP: ₹11,343 | Market Cap: ₹1,26,236 Cr | P/E: 14.3

Ram Ratna Wires – Q1 FY27 Results

CMP: ₹448 | Market Cap: ₹4,187 Cr | P/E: 32.3

Verdict

Ram Ratna Wires delivered an excellent year-on-year performance in Q1 FY27, supported by an 89% surge in revenue and a more than doubling of EBITDA and net profit, reflecting strong business momentum. On a sequential basis, however, profitability moderated, with EBITDA, net profit, and EPS declining despite higher sales, indicating margin pressure during the quarter. Overall, the company continues to maintain a strong long-term growth trajectory, though margin trends will remain an important factor to monitor in the coming quarters.

Jindal Worldwide – Q1 FY27 Results (Standalone)

CMP: ₹38.30 | Market Cap: ₹3,844 Cr | P/E: 45.4

Verdict

Jindal Worldwide reported a mixed performance in Q1 FY27. Sales remained largely stable with a modest 3% YoY growth but declined 13% sequentially. Operating performance weakened significantly as EBITDA fell 25% YoY and 27% QoQ, reflecting pressure on margins. Despite this, net profit surged 86% YoY and 24% QoQ, while EPS nearly doubled, indicating that lower finance costs, higher other income, tax benefits, or exceptional items supported profitability despite softer core operating earnings. Investors should monitor margin recovery and operating performance in the coming quarters.

SMS Pharmaceuticals Ltd. – Q1 FY27 Results

CMP: ₹374 | Market Cap: ₹3,502 Cr | P/E: 34.2

Natl. Aluminium (NALCO) – Q1 FY27 Results

CMP: ₹350 | Market Cap: ₹64,291 Cr | P/E: 9.5

Verdict

NALCO delivered an impressive quarter with strong growth across all key financial parameters. Revenue increased 39.3% YoY and 5.8% QoQ, while EBITDA surged 83.2% YoY, reflecting improved operating efficiency and healthy aluminium realizations. Net profit nearly doubled, rising 90.9% YoY and 16.3% QoQ, with EPS showing a similar trend. Despite the sharp earnings growth, the stock trades at a P/E of just 9.5, indicating attractive valuations compared to its profitability. Overall, the results highlight robust operational performance, strong margin expansion, and healthy earnings momentum.

Prataap Snacks Ltd. – Q1 FY27 Results

CMP: ₹1,160 | Market Cap: ₹2,772 Cr | P/E: 217.5

Verdict

Prataap Snacks reported a strong Q1 FY27 performance, with Sales rising 20.0% YoY to ₹492 crore, reflecting healthy demand and business momentum. EBITDA increased 12.8% YoY despite a marginal sequential decline of 1.5% QoQ. The company’s profitability improved significantly, with Net Profit surging 257.9% YoY and EPS jumping 255.2% YoY, indicating better operational efficiency and stronger bottom-line performance. Overall, the quarter was positive, driven by robust revenue growth and a sharp improvement in earnings.

EPack Prefab Technologies – Q1 FY27 Results

Price: ₹267 | M.Cap: ₹2,690 Cr | P/E: 28.4

Verdict

EPack Prefab Technologies delivered a healthy year-on-year performance with revenue rising ▲24%, supported by ▲12% growth in EBITDA and ▲13% growth in net profit. However, sequential performance softened considerably, with revenue declining ▼22%, EBITDA falling ▼25%, and net profit dropping ▼40% compared to the previous quarter. EPS also declined both year-on-year and quarter-on-quarter, reflecting margin pressure and a weaker operating performance during the quarter.

A B Lifestyle – Q1 FY27 Results

CMP: ₹94.7 | Market Cap: ₹11,555 Cr | P/E: 54.1

Verdict

Revenue and operating performance remained healthy with double-digit year-on-year growth, supported by an 11% rise in sales and a 17% increase in EBITDA. However, profitability weakened significantly on a sequential basis, with net profit and EPS declining nearly 47% QoQ. Overall, the quarter reflects strong annual growth but weak quarter-on-quarter earnings momentum.

Sarda Energy – Q1 FY27 Results (Standalone)

CMP: ₹517 | Market Cap: ₹18,204 Cr | P/E: 16.2

Verdict

Sarda Energy delivered a strong operational performance in Q1 FY27, with a sharp sequential improvement across profitability metrics. While sales were marginally lower on a year-on-year basis, significant growth in EBITDA, net profit, and EPS reflects better operating margins and improved efficiency. The robust earnings growth despite flat revenue indicates healthy cost control and a positive overall quarter.

GHCL Ltd. – Q1 FY27 Results (Standalone)

CMP: ₹438 | Market Cap: ₹4,028 Cr | P/E: 8.3

Verdict

Despite a slight decline in revenue, GHCL delivered a strong quarter with healthy improvement in profitability. EBITDA and net profit registered robust growth on both a QoQ and YoY basis, while EPS surged 38.0% YoY, highlighting improved operational efficiency and margin expansion. Overall, the results reflect resilient earnings performance despite softer sales.

Clean Science – Q1 FY27 Results (Standalone)

CMP: ₹734 | Market Cap: ₹7,802 Cr | P/E: 33.5x

Verdict

Clean Science delivered a healthy topline performance in Q1 FY27, with revenue rising 11.0% YoY and 7.6% QoQ, reflecting steady demand across its product portfolio. EBITDA remained broadly stable on a sequential basis but declined 3.4% YoY, indicating some pressure on operating margins. Despite this, net profit and EPS posted a strong 25.9% QoQ rebound and a modest 4.7% YoY increase, highlighting resilient profitability and effective cost management.

Aarti Drugs – Q1 FY27 Results

Price: ₹423 | Market Cap: ₹3,858 Cr | P/E: 20.0

Verdict

Revenue and operating performance remained strong with double-digit YoY growth and improved EBITDA. However, lower net profit and EPS despite higher operating earnings indicate pressure from below-EBITDA costs, making the quarter operationally strong but earnings mixed.

Blue Dart Express – Q1 FY27 Results

Price: ₹5,160 | Market Cap: ₹12,245 Cr | P/E: 37.8

Verdict

Blue Dart Express delivered a strong Q1 FY27 performance with healthy double-digit revenue growth and a sharp improvement in profitability. EBITDA rose 33.7% YoY, while net profit and EPS surged over 81%, supported by improved operating efficiency and margin expansion. The results indicate robust business momentum and reinforce the company’s strong position in the express logistics segment.

Sasken Technologies – Q1 FY27 Results

CMP: ₹1,812 | Market Cap: ₹2,751 Cr | P/E: 37.3

Verdict

Sasken Technologies delivered an impressive year-on-year performance in Q1 FY27, with revenue increasing 24%, EBITDA surging 119%, and net profit rising 163%, reflecting strong operational execution and improved profitability. Sequentially, revenue remained largely stable, while EBITDA, net profit, and EPS witnessed a moderate decline, indicating some margin pressure during the quarter. Overall, the company continues to demonstrate strong annual growth momentum despite a softer quarter-on-quarter earnings performance.

Narayana Hrudayalaya – Q1 FY27 Results

CMP: ₹2,029 | Market Cap: ₹41,469 Cr | P/E: 48.1x

Verdict

Narayana Hrudayalaya delivered an impressive quarter with revenue surging 78% YoY, reflecting strong patient volumes and healthy business momentum. However, EBITDA and net profit declined sequentially due to margin pressure, leading to lower profitability on a QoQ basis. Despite this, the company’s overall financial performance remains solid with positive year-on-year growth across key metrics. Sustaining margins while maintaining strong revenue growth will be the key monitorable factor in the coming quarters.

Concord Biotech – Q1 FY27 Results

Price: ₹1,421 | M.Cap: ₹14,864 Cr | P/E: 52.3

Verdict

Concord Biotech delivered a strong year-on-year performance in Q1 FY27, with healthy growth in revenue, EBITDA, net profit and EPS, reflecting robust operational execution and improving profitability. However, sequential performance moderated due to a softer quarter compared to the strong March quarter. Despite the QoQ decline, the company’s long-term earnings trajectory remains positive, supported by consistent operational strength and growth prospects.

Clean Max Enviro – Q1 FY27 Results

CMP: ₹1,336 | M.Cap: ₹15,663 Cr | P/E: 99.9

Verdict

Clean Max Enviro delivered an excellent Q1 FY27 performance, with revenue more than doubling year-on-year and EBITDA growing 58.3%, reflecting strong execution and healthy operating leverage. The company reported a significant turnaround in profitability, posting a net profit of ₹55.2 crore compared to a loss in the corresponding quarter last year. Although EPS declined 12.5% sequentially due to factors beyond operating performance, the overall results indicate robust business momentum, supported by strong revenue growth, improved profitability, and sustained operational efficiency.

Corona Remedies – Q1 FY27 Results

CMP: ₹2,099 | M.Cap: ₹12,836 Cr | P/E: 60.6

Verdict

Jupiter Life Line Hospitals – Q1 FY27 Results Snapshot

CMP: ₹332 | Market Cap: ₹10,868 Cr | P/E: 56.9x

Verdict

Jupiter Life Line Hospitals reported healthy revenue growth, with Sales rising 16% YoY and 6% QoQ, reflecting continued business expansion. However, profitability remained under pressure as EBITDA increased only 1% YoY while declining 11% QoQ. Net Profit and EPS fell 15% YoY and 25% QoQ, indicating margin pressure despite higher revenues. Overall, the quarter reflects strong top-line momentum but weaker earnings performance.

MIC Electronics – Q1 FY27 Results

CMP: ₹38.4 | Market Cap: ₹925 Cr

Verdict

MIC Electronics delivered an impressive 277% YoY revenue growth, reflecting strong business momentum compared to the previous year. The company also returned to profitability, posting a net profit of ₹2.13 crore against a loss in the previous quarter, while EPS turned positive. However, sequential performance softened, with sales declining 14% QoQ and EBITDA falling 68.2% QoQ, indicating pressure on operating margins. Overall, the results remain positive on a year-on-year basis but mixed on a quarter-on-quarter basis. Investors should closely monitor the company’s ability to sustain profitability and improve operating margins in the coming quarters.